| Literature DB >> 32526993 |
Sylwia Michlewska1,2, Maksim Ionov2, Aleksandra Szwed2, Aneta Rogalska3, Natalia Sanz Del Olmo4,5, Paula Ortega4,5, Marta Denel3, Damian Jacenik6, Dzmitry Shcharbin7, Francisco Javier de la Mata4,5, Maria Bryszewska2.
Abstract
Ruthenium atoms located in the surfaces of carbosilane dendrimers markedly increase their anti-tumor properties. Carbosilane dendrimers have been widely studied as carriers of drugs and genes owing to such characteristic features as monodispersity, stability, and multivalence. The presence of ruthenium in the dendrimer structure enhances their successful use in anti-cancer therapy. In this paper, the activity of dendrimers of generation 1 and 2 against 1301 cells was evaluated using Transmission Electron Microscopy, comet assay and Real Time PCR techniques. Additionally, the level of reactive oxygen species (ROS) and changes of mitochondrial potential values were assessed. The results of the present study show that ruthenium dendrimers significantly decrease the viability of leukemia cells (1301) but show low toxicity to non-cancer cells (peripheral blood mononuclear cells-PBMCs). The in vitro test results indicate that the dendrimers injure the 1301 leukemia cells via the apoptosis pathway.Entities:
Keywords: 1301 human lymphoblastic leukemia; carbosilane dendrimer; cytotoxicity; drug delivery; ruthenium
Mesh:
Substances:
Year: 2020 PMID: 32526993 PMCID: PMC7312499 DOI: 10.3390/ijms21114119
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1The effect of ruthenium-terminated carbosilane dendrimers (CRD) on viability of peripheral blood mononuclear cells (PBMCs) and 1301 cells after 24 h treatment. The values are mean ± SD of n ˃ 6. * Statistically significant differences compared to the control cells (* p < 0.05).
Inhibitor concentrations (IC50 ± SD (µmol/L)) resulting in 50% dendrimer-mediated reduction of 1301 cell viability.
| 24 h | 48 h | |
|---|---|---|
| CRD13 | 3.80 ± 0.36 | 3.65 ± 2.90 |
| CRD27 | 4.90 ± 1.50 | 3.78 ± 2.70 |
Figure 2Light microscopy of semi-thin sections of 1301 cells: (A) untreated cells, (B) cells treated with CRD13 dendrimer at 2.5 µmol/L, (C) cells treated with CRD27 dendrimer at 5 µmol/L. Scale bar = 10 µm.
Figure 3Ultrastructural changes in 1301 cells (A–C). Cells influenced by CRD13 at 2.5 µmol/L (D–F) or CRD27 at 5 µmol/L (G–I). Abbreviations: N—nucleus. Nu—nucleolus. M—mitochondria. MVB—multi-vesicular bodies. LB—lamellar bodies. L—lipids. GA—Golgi apparatus. ER—endoplasmic reticulum. *—vesicle containing CRD dendrimers.
Figure 4DNA (%) in the comet tail of the control cells and of 1301 cells treated with different concentrations of CRD13 and CRD27 dendrimers. Fifty cells were analyzed in each treatment. The values are the mean ± SD of three independent experiments. *Statistically significant differences from the control cells (* p < 0.05).
Changes in reactive oxygen species (ROS) levels in 1301 cells under the influence of ruthenium dendrimers CRD13 and CRD27. The values are mean ± SD.
| Incubation Time | CRD13 Concentration (μmol/L) | CRD27 Concentration (μmol/L) | ||||||
|---|---|---|---|---|---|---|---|---|
| 0.5 | 1 | 2.5 | 5 | 0.5 | 1 | 2.5 | 5 | |
|
| 126.98 ± 8.80 | 127.27 ± 9.20 | 140.28 ± 10.51 | 140.81 ± 9.40 | 127.40 ± 9.52 | 126.87 ± 9.63 | 138.86 ± 8.48 | 141.19 ± 10.50 |
|
| 109.07 ± 5.00 | 109.70 ± 5.07 | 121.16 ± 0.99 | 127.89 ± 4.97 | 114.79 ± 2.88 | 116.36 ± 8.39 | 121.38 ± 6.34 | 122.18 ± 6.17 |
|
| 101.37 ± 2.54 | 100.68 ± 1.41 | 97.37 ± 2.08 | 95.49 ± 3.00 | 103.671 ± 1.73 | 99.47 ± 2.85 | 98.67 ± 1.89 | 94.02 ± 3.81 |
|
| 86.92 ± 8.43 | 90.64 ± 5.09 | 89.92 ± 7.65 | 93.47 ± 5.76 | 94.69 ± 4.48 | 89.28 ± 5.38 | 87.78 ± 3.44 | 88.08 ± 5.32 |
Changes in mitochondrial potential (ΔΨm) in 1301 cells under the influence of ruthenium dendrimers CRD13 and CRD27. The values are mean ± SD.
| Incubation Time | CRD13 Concentration (μmol/L) | CRD27 Concentration (μmol/L) | ||||||
|---|---|---|---|---|---|---|---|---|
| 0.5 | 1 | 2.5 | 5 | 0.5 | 1 | 2.5 | 5 | |
|
| 97.23 ± 3.28 | 96.43 ± 5.85 | 115.00 ± 3.55 | 122.145 ± 5.67 | 97.51 ± 2.53 | 99.62 ± 1.81 | 98.84 ± 1.44 | 109.09 ± 6.29 |
|
| 103.56 ± 5.56 | 109.63 ± 1.9 | 123.76 ± 1.60 | 140.56 ± 5.35 | 103.30 ± 4.43 | 109.79 ± 5.63 | 111.53 ± 13.53 | 138.58 ± 10.91 |
|
| 96.03 ± 6.65 | 96.63 ± 9.74 | 105.71 ± 14.06 | 120.40 ± 16.76 | 88.74 ± 9.48 | 92.79 ± 11.25 | 141.53 ± 16.90 | 176.4 ± 15.82 |
|
| 99.59 ± 3.28 | 97.92 ± 3.89 | 108.13 ± 6.15 | 119.94 ± 13.03 | 86.89 ± 5.72 | 84.02 ± 4.27 | 105.69 ± 10.14 | 120.51 ± 10.31 |
Figure 5Relative anti-apoptotic protein expression values after 24 h incubation of 1301 cells with CRD13 and CDR27 at different concentrations. * Statistically significant differences from control cells (* p < 0.05, ** p < 0.01).
Figure 6The structure and molecular weight of the 1st (CDR13) and 2nd (CRD27) generations of cationic carbosilane ruthenium (II) dendrimers.